Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives $46.43 Consensus Target Price from Analysts

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTHGet Free Report) have been given a consensus recommendation of “Buy” by the ten brokerages that are covering the firm, MarketBeat reports. Eight equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $46.43.

A number of equities research analysts have weighed in on the stock. Oppenheimer upped their price objective on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an “outperform” rating in a report on Monday, November 11th. HC Wainwright restated a “buy” rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a research note on Monday, November 11th. TD Cowen began coverage on Dianthus Therapeutics in a research note on Friday, December 20th. They set a “buy” rating for the company. Finally, Raymond James raised Dianthus Therapeutics to a “moderate buy” rating in a report on Thursday, December 12th.

Get Our Latest Research Report on DNTH

Dianthus Therapeutics Stock Up 6.4 %

NASDAQ DNTH opened at $23.20 on Friday. The stock’s 50 day moving average is $24.77 and its 200 day moving average is $26.57. The firm has a market capitalization of $686.65 million, a PE ratio of -9.28 and a beta of 1.75. Dianthus Therapeutics has a twelve month low of $10.65 and a twelve month high of $33.77.

Dianthus Therapeutics (NASDAQ:DNTHGet Free Report) last announced its earnings results on Thursday, November 7th. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). The business had revenue of $2.17 million for the quarter, compared to the consensus estimate of $1.07 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. On average, research analysts anticipate that Dianthus Therapeutics will post -2.61 earnings per share for the current year.

Institutional Investors Weigh In On Dianthus Therapeutics

Institutional investors have recently modified their holdings of the business. Quest Partners LLC lifted its stake in Dianthus Therapeutics by 112,400.0% during the 3rd quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock valued at $31,000 after acquiring an additional 1,124 shares during the period. The Manufacturers Life Insurance Company bought a new position in Dianthus Therapeutics during the second quarter valued at approximately $236,000. SG Americas Securities LLC boosted its holdings in Dianthus Therapeutics by 104.0% in the third quarter. SG Americas Securities LLC now owns 8,839 shares of the company’s stock worth $242,000 after purchasing an additional 4,506 shares during the last quarter. Fred Alger Management LLC grew its position in Dianthus Therapeutics by 52.5% in the 3rd quarter. Fred Alger Management LLC now owns 9,633 shares of the company’s stock worth $264,000 after purchasing an additional 3,316 shares during the period. Finally, WINTON GROUP Ltd purchased a new stake in Dianthus Therapeutics during the 2nd quarter valued at $265,000. 47.53% of the stock is owned by hedge funds and other institutional investors.

About Dianthus Therapeutics

(Get Free Report

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.

Further Reading

Analyst Recommendations for Dianthus Therapeutics (NASDAQ:DNTH)

Receive News & Ratings for Dianthus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dianthus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.